Shubham Singh has been a journalist since 2018, covering business and consumer technology for leading media organizations such as India Today, CNBC-TV18, Zee News, and others. As a Reporter for Medtech Insight, he covers policy, regulation, and digital tech. Outside work, Shubham is an avid traveler, foodie, and fitness enthusiast, balancing his schedule with gym sessions, trekking, and OTT binge-watching.

Latest from Shubham Singh

Remepy To Embed AI In Next-Gen Digital Therapeutics For Personalized Neuroimmune Modulation

Remepy is exploring two potential regulatory pathways to support this strategy. The first is a combination product pathway that would formally integrate software and drug into a single therapeutic entity. The second is the FDA’s Prescription Drug Use-Related Software (PDURS) pathway.

India’s MedTech Future Hinges On Regulatory Reform And Global Alignment: MTaI’s Pavan Choudary

In this in-depth interview with Medtech Insight, Pavan Choudary unpacks the implications of recent free trade agreements (FTAs) such as India’s with the UK, the potential fallout from new US tariffs on Indian device exports, and the pressing need for regulatory harmonization.

Harbinger Health Showcases Two-Tiered MCED Test With Strong Specificity And Per-Cancer Accuracy

With a test platform designed to mirror the biological diversity of cancer, Harbinger Health is moving beyond traditional performance measures to introduce cancer-specific sensitivity and “intrinsic accuracy” as cornerstones of its clinical narrative.

Intuitive Surgical Projects $165M Tariff Hit In 2025, Says Wait-And-See On Mitigation

Despite near-term cost pressures, Intuitive Surgical is expanding manufacturing and R&D in North America and Europe to meet demand for Ion, X and Xi systems.

Thermo Fisher Cuts Annual Profit Outlook Amid Estimated $400M Tariff Hit

Thermo Fisher is aggressively managing its supply chain and cost base using its Practical Process Improvement (PPI) Business System. The company is also increasing investments in US-based manufacturing and R&D, with around $2bn allocated to bolster domestic operations.

HistoSonics’ Edison System Gains Limited UK Access, While Awaiting CE Marking

While HistoSonics is awaiting the CE mark in Europe, it hit a major milestone by securing early limited market access in Great Britain under a Unmet Clinical Need Authorization (UCNA), bringing its noninvasive histotripsy treatment to patients with liver tumors.